Vol. 28 No. 1 (2017): Turkish Journal of Gastroenterology

Published: 2017-01-01

Review

Consensus Report on Gastroesophageal Reflux Disease in Turkey

Serhat Bor

(S1-S2)

DOI: https://doi.org/10.5152/tjg.2017.01
Full Text PDF Abstract

Method

Gülen Hatemi

(S3-S3)

DOI: https://doi.org/10.5152/tjg.2017.02
Full Text PDF Abstract

How is the gastroesophageal reflux disease prevalence, incidence, and frequency of complications (stricture/esophagitis/Barrett’s esophagus/ carcinoma) in Turkey compared to other geographical regions globally?

Serhat Bor, Elif Sarıtaş Yüksel

(S4-S9)

DOI: https://doi.org/10.5152/tjg.2017.03
Full Text PDF Abstract

How is gastroesophageal reflux disease classified?

Filiz Akyüz, Özlem Mutluay Soyer

(S10-S11)

DOI: https://doi.org/10.5152/tjg.2017.04
Full Text PDF Abstract

What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)

Rukiye Vardar, Muharrem Keskin

(S12-S15)

DOI: https://doi.org/10.5152/tjg.2017.05
Full Text PDF Abstract

Indications of 24-h esophageal pH monitoring, capsule pH monitoring, combined pH monitoring with multichannel impedance, esophageal manometry, radiology and scintigraphy in gastroesophageal reflux disease?

Rukiye Vardar, Muharrem Keskin

(S16-S21)

DOI: https://doi.org/10.5152/tjg.2017.06
Full Text PDF Abstract

To whom and when the upper gastrointestinal endoscopy is indicated in gastroesophageal reflux disease? What is the role of routine esophageal biopsy? Which endoscopic esophagitis classification should be used?

Taylan Kav

(S22-S25)

DOI: https://doi.org/10.5152/tjg.2017.07
Full Text PDF Abstract

How should we describe, diagnose and observe the Barrett's esophagus?

Hakan Akın, Yücel Aydın

(S26-S30)

DOI: https://doi.org/10.5152/tjg.2017.08
Full Text PDF Abstract

Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?

Hakan Akın, Yücel Aydın

(S31-S32)

DOI: https://doi.org/10.5152/tjg.2017.09
Full Text PDF Abstract

The role of lifestyle changes in gastroesophageal reflux diseases treatment

Ülkü Dağlı, İsmail Hakkı Kalkan

(S33-S37)

DOI: https://doi.org/10.5152/tjg.2017.10
Full Text PDF Abstract

Which drugs are risk factors for the development of gastroesophageal reflux disease?

Zeynel Mungan, Binnur Pınarbaşı Şimşek

(S38-S43)

DOI: https://doi.org/10.5152/tjg.2017.11
Full Text PDF Abstract

Which diseases are risk factors for developing gastroesophageal reflux disease?

Filiz Akyüz, Özlem Mutluay Soyer

(S44-S47)

DOI: https://doi.org/10.5152/tjg.2017.12
Full Text PDF Abstract

Medical treatment of gastroesophageal reflux disease

Serhat Bor, İsmail Hakkı Kalkan

(S48-S52)

DOI: https://doi.org/10.5152/tjg.2017.13
Full Text PDF Abstract

Treatment of reflux disease during pregnancy and lactation

Ülkü Dağlı, İsmail Hakkı Kalkan

(S53-S56)

DOI: https://doi.org/10.5152/tjg.2017.14
Full Text PDF Abstract

What is the long term acid inhibitor treatment in gastroesophageal reflux disease? What are the potential problems related to long term acid inhibitor treatment in gastroesophageal reflux disease? How should these cases be followed?

İbrahim Hatemi, Sinem Nihal Esatoğlu

(S57-S60)

DOI: https://doi.org/10.5152/tjg.2017.15
Full Text PDF Abstract

Gastroesophageal reflux disease and the relationship with Helicobacter pylori

Zeynel Mungan, Binnur Pınarbaşı Şimşek

(S61-S67)

DOI: https://doi.org/10.5152/tjg.2017.16
Full Text PDF Abstract

When proton pump inhibitors are compared, are there specific cases in which a certain proton pump inhibitors should be particularly preferred?

Altay Çelebi, Hasan Yılmaz

(S68-S70)

DOI: https://doi.org/10.5152/tjg.2017.17
Full Text PDF Abstract

What is proton pump inhibitors unresponsiveness in gastroesophageal reflux disease? How should these cases be managed?

Altay Çelebi, Hasan Yılmaz

(S71-S72)

DOI: https://doi.org/10.5152/tjg.2017.18
Full Text PDF Abstract